Proceedings of the National Academy of Sciences of the United States of America · 1996
Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.
Клинический случайСравнительное исследованиеСтатьяПоддержка правительства СШАПоддержка службы здравоохранения СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McElrath M J, Corey L, Greenberg P D, Matthews T J, Montefiori D C, Rowen L, Hood L, Mullins J I
Аннотация
With efforts underway to develop a preventive human immunodeficiency virus type 1 (HIV-1) vaccine, it remains unclear which immune responses are sufficient to protect against infection and whether prior HIV-1 immunity can alter the subsequent course of HIV-1 infection. We investigated these issues in the context of a volunteer who received six HIV-1LAI envelope immunizations and 10 weeks thereafter acquired HIV-1 infection through a high-risk sexual exposure. In contrast to nonvaccinated acutely infected individuals, anamnestic HIV-1-specific B- and T-cell responses appeared within 3 weeks in this individual, and neutralizing antibody preceded CD8+ cytotoxic responses. Despite an asymptomatic course and an initial low level of detectable infectious virus, a progressive CD4+ cell decline and dysfunction occurred within 2 years. Although vaccination elicited immunity to HIV-1 envelope, which was recalled upon HIV-1 exposure, it was insufficient to prevent infection and subsequent immunodeficiency.
Предметные рубрики MeSH
AIDS VaccinesAdultAmino Acid SequenceB-LymphocytesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesGene Products, envHIV AntibodiesHIV Envelope Protein gp160HIV InfectionsHIV SeropositivityHIV-1Homosexuality, MaleHumansMaleMolecular Sequence DataProtein PrecursorsRisk-TakingSmallpox VaccineT-LymphocytesTime FactorsVaccines, Synthetic